Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: samcat9 who wrote (1444)	7/11/1998 9:47:00 PM
From: HairBall	Respond to of 2887

Samcat9: Sorry, I do not need you to tell me weather I should or should not invest in this stock. I will make up my own mind, through my on analysis! I am interested in reading post with genuine information that will help me make a decision. I don't care if I agree or disagree with the conclusion, I still appreciate the effort. Hey, you can't buy if no one wants to sell or you can't sell if no one wants to buy. People, taking different positions in the market, make up the market! GET IT! Regards, LG

To: samcat9 who wrote (1444)	7/13/1998 1:42:00 PM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 2887

The OmniStentO provides a foundation for support to a weakened vessel. It is manufactured using a proprietary, patented process that makes a one-piece, endless loop without soldering or annealing. The company has two distinct configurations: the coil stent, for support of a longitudinal section of a vessel; and the bifurcated stent, Y-shaped in design for use in aortic bifurcation (small versions may be used at any branched blood vessel). Unique in design, no other company has met the challenge of manufacturing and deploying a bifurcated stent. Made of nitinol, the company's stents have memory properties that allow them to return to a predetermined shape and adjust to the size of the artery. The stents are available in both balloon- expandable and self-expandable delivery systems. This technology is supported by two existing patents and a related Continuation In Part, filed in June 1995. Clinical trials are anticipated to begin in late 1998.